SEARCH

SEARCH BY CITATION

References

  • 1
    Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003; 9: 41835.
  • 2
    Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 5461.
  • 3
    Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16(Suppl 2): 1623.
  • 4
    Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 235863.
  • 5
    Coppola A, Santoro C, Franchini M, Tagliaferri A, Di Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16(Suppl 1): 139.
  • 6
    Matzinger P. The danger model: a renewed sense of self. Science 2002; 8: 7682.
  • 7
    Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 464854.
  • 8
    Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 138390.
  • 9
    Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA; Paediatric Working Party of the UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17: 2827.
  • 10
    Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, Brown SA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 7682.
  • 11
    Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91: 9104.
  • 12
    Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11: 7983.
  • 13
    Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 4227.
  • 14
    Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 25662.
  • 15
    Klukowska A, Komrska V, Jansen M, Laguna P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate: interim report from an ongoing prospective clinical study. Haemophilia 2011; 17: 399406.
  • 16
    Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011; 17: 6259.
  • 17
    Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A; Study Group on Factors involved in formation of inhibitors to factor VIII and IX preparations. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia 2011; 17: 7716.
  • 18
    Celkan T, Ozdemir N. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey. Haemophilia 2011; 17: e8401.
  • 19
    Liesner R, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 9738.
  • 20
    Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 2728.
  • 21
    Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG; Ewenstein BM; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 42837.
  • 22
    Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J; The ReFacto St. Louis Study Group. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 44451.
  • 23
    Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 257681.
  • 24
    Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian hemophilia primary prophylaxis study. J Thromb Haemost 2006; 4: 122836.
  • 25
    Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost 2007; 98: 118892.
  • 26
    Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 53544.
  • 27
    Blanchette VS, Shapiro AD, Liesner RJ, Hernandez Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM, for the rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 131926.
  • 28
    den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia 2009; 15: 12158.
  • 29
    Petrini P, Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study. Haemophilia 2009; 15: 17583.
  • 30
    Young JH, Liu HC, Hsueh EJ, Huang ML, Peng CT, Chen RL, Maas-Enriquez M, Achilles K. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A. Haemophilia 2009; 15: 96870.
  • 31
    Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O’Brien A, Hayward B, Udata C, Roth DA, Arkin S. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 86980.
  • 32
    Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 839.
  • 33
    Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 86677.
  • 34
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Vince Jenkins P, O’Donnell JS. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE). Haemophilia 2011; 17: 40711.
  • 35
    Dmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O’Shaughnessy D, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Clinical assessment of Optivate, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. Haemophilia 2011; 17: 45662.
  • 36
    Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 70010.
  • 37
    Matysiak M, Bobrowska H, Balwierz W, Chybicka A, Kowalczyk JR, Shaikh-Zaidi R, Gillanders K, Dash CH. Clinical experience with Optivate, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. Haemophilia 2011; 17: 73742.
  • 38
    Gouw SC, van den Berg HM, Auerswald G, Carcao M, Chalmers E, Chambost H, Fischer K, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Pérez Garrido R, Rafowicz A, Williams M, van der Bom JG. Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN Study. Haemophilia 2012; 18(Suppl 1): 34 (abstract).
  • 39
    ter Avest P, Fischer K, Mancuso ME, Santagostino E, Jiménez Yuste V, van den Berg HM, van der Bom J, CANAL Study Group. Risk stratification for inhibitor development at first treatment for severe haemophilia A patients: a tool for clinical practice. J Thromb Haemost 2008; 6: 204854.
  • 40
    Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 7994.
  • 41
    Hay CR, Palmer B, Chalmers E, Liesner R, Maclean R, Rangarajan S, Williams M, Collins PW; United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). Incidence of FVIII inhibitors throughout life in severe hemophilia A in United Kingdom. Blood 2011; 117: 636770.